Shortage of purified protein derivative for tuberculosis testing

The Lancet

Volumn 384, Issue 9959, 2014, Pages 2026-

  Tebruegge, Marc ^a   Bogyi, Matthias ^b   Soriano Arandes, Antoni ^c   Kampmann, Beate ^d  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b WILHELMINEN HOSPITAL   (Austria)

^c Programa Especial de Malalties Infeccioses Vall d'Hebron Drassanes   (Spain)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULIN;

HEALTH CARE AVAILABILITY; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LETTER; PROPHYLAXIS; SCREENING TEST; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; DIAGNOSTIC USE; EUROPE;

EUROPE; HUMANS; TUBERCULIN; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84919665074     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62335-7     Document Type: Letter

References (3)

1. M Pai, CM Denkinger, SV Kik et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection Clin Microbiol Res 2 2014 3 20
2. SM Newton, AJ Brent, S Anderson, E Whittaker, B Kampmann Paediatric tuberculosis Lancet Infect Dis 8 2008 498 510
3. TG Connell, M Tebruegge, N Ritz, P Bryant, N Curtis The potential danger of a solely interferon-gamma release assay-based approach to testing for latent Mycobacterium tuberculosis infection in children Thorax 6 2011 263 264